Recent Hologic Acquisition Bolder Surgical Included on Fast Company’s Annual List of World’s Most Innovative Companies

Company Recognized for Pioneering Advanced Energy Vessel Sealing Surgical Devices, Including Hologic's CoolSeal® Vessel Sealing Portfolio

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that recently acquired Bolder Surgical was included on Fast Company’s annual list of the World’s Most Innovative Companies. Bolder Surgical, a developer and manufacturer of advanced energy vessel sealing and dissection tools for surgical gynecologists in both laparoscopic and open procedures was acquired by Hologic in November 2021.

Hologic notes Bolder ranked fifth on the list of Most Innovative Medical Device Companies, a sector highlighting companies that are creatively using technology to improve patient care. The full list of Most Innovative Companies consisted of 528 companies chosen by a team of editors and reporters for Fast Company from thousands of applicants across the globe.

“We’re thrilled that Bolder — the newest member of our Surgical business — has captured a spot on Fast Company’s prestigious list of the most innovative companies making an impact around the globe,” said Essex Mitchell, Hologic’s Division President, Surgical. “The CoolSeal devices have already proven to be an important addition to our growing Surgical portfolio, and we’re looking forward to seeing how we can continue to improve efficiency for surgeons and hospitals, while helping to improve outcomes for patients, through these innovative products.”

Bolder was recognized for its innovation in designing surgical devices, in particular the CoolSeal® devices, which allows for dissection, vessel sealing and dividing all in one tool. The ability to use a combination device improves surgical efficiency by reducing the need for instrument exchanges. In addition, Bolder’s CoolSeal® Mini 3 mm vessel sealer and the JustRight® 5 mm stapler are designed for small surgical spaces such as in pediatric cases, which can help reduce the need for larger, overpowered instruments.

Hologic’s surgical product line also includes the NovaSure® endometrial ablation system for the treatment of abnormal uterine bleeding, the MyoSure® tissue removal devices for the removal of intrauterine fibroids and polyps, the Acessa® laparoscopic radiofrequency ablation system for the treatment of fibroids, and the Fluent® fluid management system for streamlining hysteroscopic procedures.

According to Fast Company, the Most Innovative Companies list “has been the definitive source for recognizing the organizations that are transforming industries and shaping society” since it began in 2008.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”